SUMMARY REPORT ICH MC TELECONFERENCE 26 September 2017

Similar documents
SUMMARY REPORT ICH MC TELECONFERENCE April 13, 2017

SUMMARY REPORT ICH MC TELECONFERENCE 24 January 2018

Minutes ICH Management Committee Meeting Montreal, Canada May 29 - June 1, 2017

FINAL MINUTES ICH Assembly Geneva, Switzerland November 2017

FINAL MINUTES ICH Assembly May 31 & June 1, 2017, Montreal, Canada

Portland, Oregon, USA (Portland Marriott Downtown Waterfront Hotel)

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

MEETING REPORT ICH Steering Committee November 2013, Osaka, Japan

Overview of ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.

ASSEMBLY AGENDA PAPERS. May 31 & June 1, 2017 Montreal, Canada

ICH ASSOCIATION 2016 ANNUAL REPORT

Trends in the development of regulatory systems by the example of ICH countries

Recent Development of ICH GCG

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Yokohama, Japan (Yokohama Royal Park Hotel)

E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs

Q11 Development and Manufacture of Drug Substances--Questions and Answers

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Rules of Procedure of the Assembly

Provisional agenda (annotated)

Addendum to ICH E6 (R2)

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Consideration on Global Harmonization

ICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY

Topical Peer Review 2017 Ageing Management of Nuclear Power Plants

EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS

D6.3 Communication management routines and infrastructure implemented

GPP Subcommittee Meeting

An introduction to Codex and basic principles of standards development (Code of Good Practice for standards development)

Memorandum of Understanding between MHRA and the General Pharmaceutical Council

CEN Technical Committees Mode of operations

Guidance for the Tripartite model Clinical Investigation Agreement for Medical Technology Industry sponsored research in NHS Hospitals managed by

GCP Inspection by PMDA

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

Quality Risk Management ICH Q9

Thursday 29 January 2015 at 5.00pm Held at EDF Energy, Doxford International Business Park, Sunderland

Developing an Incremental Proposal for EU gas transmission. Draft Project Plan

BEST PRACTICE GUIDE FOR DECENTRALISED AND MUTUAL RECOGNITION PROCEDURES

Research Staff Training

Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination

Role and Vision of PMDA

Standard Operating Procedures

Updated Proposal by Brazil and France as co-chairs of the REDD+ Partnership:

1. Introduction, purpose of this Standard Operating Procedure (SOP)

Ramsar Regional Initiatives (RRIs) News from the Regional Initiative Workshop 22 November

Classification, Language, and Concept Representation IMIA WG 6

Licensing of a Nuclear Installation. November 11th 2010 Licensing of a Nuclear Installation 1

LEBANON 14 July In Brief

Why do we need an addendum to ICH E6?

Regional Update ASEAN PPWG

14TH CONGRESS OF 9 10 JUNE 2014, GENEVA, ROOM IX, ILO BUILDING

Invitation For Tender

Appointment of Experts of the Independent Technical Advisory Panel

Looking at our Achievements and the Way Forward. The 5 th pharmaceutical compliance congress & best practices forum Istanbul - Turkey

THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA THIRD REPLENISHMENT ( ) UPDATE ON THE IMPLEMENTATION OF THE NEW GRANT ARCHITECTURE

Independent Group Advising (NHS Digital) on the Release of Data (IGARD)

EBRD Shareholder Special Fund interim evaluation

4. Multi Stakeholder: Late & Early Dialogue

Structure and Responsibilities of the 21st SMSUK Committee

2. Board Update LS informs the Working Group members on the latest (major) Board Issues:

Accreditation Guidelines

EU Stress Tests and National Action Plans

PATHWAYS FOR STANDARDS DEVELOPMENT. Developing internationally aligned Australian Standards in the national interest

Department of Economic and Social Affairs Statistics Division ESA/STAT/AC.344/L.3 05 December Report

Working Party on Information Security and Privacy

Content Sheet 11-1: Overview of Norms and Accreditation

ICH Regulators Forum. Dr Peter Arlett EU

The New EU PV Legislation: View from the European Commission

Agenda item for discussion IPDC fundraising and communication

Version Number: 004 Controlled Document Sponsor: Controlled Document Lead:

Rank review group. Terms of reference

Terms of Reference Approved 30 April 2015/ Revised 29 September 2016

Development of a draft five-year global strategic plan to improve public health preparedness and response

IEC-IEEE development of dual logo standards on condition monitoring Update November Kjell Spång KS miltek

Now We are Getting to the Hard Parts: An Analysis Files Perspective

Headline Goal approved by General Affairs and External Relations Council on 17 May 2004 endorsed by the European Council of 17 and 18 June 2004

Brokerage for the first ProSafe Call Dina Carrilho Call Secretariat Foundation for Science and Technology (FCT), Portugal

SADC Collaborative Medicines Registration Initiative (Zazibona)

Appendix 2 LIVERPOOL STATEMENT OF COMMUNITY INVOLVEMENT

European network of paediatric research (Enpr-EMA)

Official Integrated Implementation Training Workshops for ICH Q8, Q9 and Q10

Provincial Niagara to GTA Corridor Study Community Meeting

Making sure all licensed doctors have the necessary knowledge of English to practise safely in the UK

Meeting report series. Report of the 16th Therapies Scientific Committee Meeting

Meeting of the Quality and Accountability Initiatives

Work Plan for Re-Development of UH Hilo s Mission and Vision UPDATED

FDA Information Day: who should attend. Detailed Update on the Latest Information for ICSR and IDMP. Individual Case Safety Reports

Auditing of Clinical Trials

Mark Drakeford Minister for Health & Social Services

GDUFA II: Requests for Reconsideration

NATIONAL GUIDELINES FOR THE ACCREDITATION OF NURSING AND MIDWIFERY PROGRAMS LEADING TO REGISTRATION AND ENDORSEMENT IN AUSTRALIA

General Assembly Twenty-first session Medellin, Colombia, September 2015 Provisional agenda item 8(II)(c)

PMR PROJECT IMPLEMENTATION STATUS REPORT (ISR)

Guidelines for Grant Applicants

To provide Council with a draft copy of the Factual Information Communication Campaign literature.

Kingston Clinical Commissioning Group Report Summary

Army Posture Statement Concept Briefing

Forest Carbon Partnership Facility 4f. Update on Monitoring and Evaluation (M & E) Framework

49th DIRECTING COUNCIL 61st SESSION OF THE REGIONAL COMMITTEE

Promote and strengthen international collaboration to reduce road traffic injuries. Preamble

101 Davenport Road, Toronto, Ontario Canada M5R 3P1 Telephone Toll Free (Ontario) Facsimile

Transcription:

23 October 2017 SUMMARY REPORT ICH MC TELECONFERENCE 26 September 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ICH Secretariat, Chemin des Mines 9, 1202 Geneva, Switzerland Telephone: +41 (22) 338 32 06 - admin@ich.org, http://www.ich.org

LIST OF PARTICIPANTS: ICH Management Committee Members/Observers Ms. Lenita Lindström Dr. Spiros Vamvakas Dr. Sabine Luik Mr. Pär Tellner Dr. Theresa Mullin (Chair) Ms. Joan Blair Ms. Pujita Vaidya Ms. Catherine Parker Dr. Celia Lourenco Dr. Hironobu Hiyoshi Dr. Masafumi Yokota Dr. Toshiyoshi Tominaga (Vice Chair) MHLW/PMDA, Japan Dr. Nobumasa Nakashima MHLW, Japan Mr. Naoyuki Yasuda MHLW/PMDA, Japan Mr. Jerry Stewart PhRMA Ms. Cordula Landgraf Swissmedic, Switzerland ICH MC Coordinators Dr Georgios Balkamos Mr. Pär Tellner Ms. Amanda Roache Mr. Nick Orphanos Mr. Mitsuo Mihara Mr. Fumihito Takanashi Ms. Camille Jackson MHLW, Japan PhRMA Technical Coordinators: Ms. Chieko Hirose Ms. Michelle Limoli MHLW/PMDA, Japan Other Participants: Dr. Tomas Salmonson Dr. Martin Harvey Dr. Sarah Adam Dr. Gabriela Zenhäusern IFPMA WHO ICH Secretariat: Dr. Véronique Kuntzelmann Dr. Anne Latrive Dr. Dawn Ronan 1

SUMMARY REPORT MC Chair: Dr. Theresa Mullin, MC Vice-Chair: Dr. Toshiyoshi Tominaga, MHLW/PMDA, Japan 1. ADOPTION OF THE AGENDA Dr. Mullin (MC Chair, ) welcomed all participants. The agenda was adopted without modifications, but with a reordering of topics (item 5 was discussed first, and then followed the order 2, 3, 4, 6, 7). 2. ADOPTION OF THE MINUTES OF THE MONTREAL MEETING AND OF THE REPORT OF THE PREVIOUS TELECONFERENCE The MC approved as final the MC minutes of the Montreal meeting (MC2017/07) and publication on the ICH website; The MC approved the Report of the teleconference held on 6 September 2017 and publication on the ICH website. 3. APPOINTMENT OF ELECTED MC REPRESENTATIVES The MC was updated on the comments received from MC Members on the proposed document entitled Considerations for assessing the eligibility criteria for appointing Elected Representatives in the ICH Management Committee and the main changes made in view of these comments. The MC agreed to further consider the next steps for the document at its next TC on 3 October; The MC agreed that the applications for elected MC Representatives received from the ICH Members should be shared with all Members of the Assembly. 4. ICH MEMBERSHIP AND OBSERVERSHIP APPLICATIONS The MC was updated on the status of Membership/Observership applications. MC Action/Decision: The MC agreed that the initial assessment of applications for elected MC Representatives would be led by the Secretariat with input from the Membership Subcommittee as necessary. 5. NEW TOPIC PROPOSALS AND STRATEGIC DISCUSSIONS The MC was updated on the progress of the New Topics Subcommittee, in particular with regards to amending the processes for New Topics, Strategic Reflection Papers and strategy of harmonisation. The MC noted that all MC Members are represented in the New Topics Subcommittee and that all MC Members would need to be represented on the subcommittee going forward. 2

New Topics proposals The MC noted that, in the revised New Topics process, New Topics proposals should be submitted to the Secretariat at the latest on 15 December 2017. The MC supported allocating between 60 minutes and 120 minutes at both the MC and Assembly meetings on New Topics Proposals and Strategic Discussions; The MC supported the organisation of an interim meeting for the New Topics Subcommittee to begin on Monday 26 March 2018 in London, UK, hosted by and noted that the schedule and exact number of days (between 1 and 3) should be further discussed. The MC also noted that the Financial Subcommittee is working on elaborating a proposal for the organisation of an MC interim meeting, to be discussed at the Geneva meeting. The MC endorsed the updated supporting documents put together by the New Topics Subcommittee describing the New topics selection process. Strategic discussions The MC noted that the updated Quality Reflection Paper on Advancing Pharmaceutical Quality Standards had been received and that a very preliminary draft Reflection Paper on Vaccines would also be circulated by mid-october, for discussion at the Geneva meeting. The MC noted that one or two additional suggestions for future strategic priorities may also be submitted later, for discussion at the Geneva meeting. The MC supported the intent of inviting Assembly Members to propose topics to be included in the long-term strategy of the ICH organisation (e.g. strategic priorities and Reflection Papers) for preliminary discussion by the MC for recommendation and subsequent decision by the Assembly and endorsed the supporting documents put together for this purpose by the New Topics Subcommittee. The MC also agreed that further reflection was needed on how to organise the discussions of the Assembly to enable more engagement and participation of the Assembly Representatives and Delegates; The MC supported that the Quality Reflection Paper on Advancing Pharmaceutical Quality Standards will be discussed at the MC TC on 17 October with comments to be provided to the Secretariat by 10 October, with the aim of providing it to the Assembly in the Agenda Papers Package ahead of the Geneva meeting. 6. COMMUNICATION The MC was updated on the activities undertaken since the Montreal meeting, notably in relation to the implementation of the Transparency policy. The MC agreed that pending biographies and photos from MC and Assembly Members Representatives and Observers Delegates should be sent to the ICH Secretariat as soon as possible in order to be published on the ICH website ahead of the Geneva meeting, in line with the transparency policy approved by the Assembly at the Montreal meeting; The MC agreed on the principle of issuing an interim press release to update stakeholders on ICH guidelines having reached key milestones since the Montreal meeting and on the publication of experts names on the ICH website. 3

7. DATES OF NEXT TELECONFERENCE AND MEETINGS Teleconferences 3 October MC Policy 11 October MC Policy 17 October MC Policy Face-to-Face Meetings 11-16 November 2017 Geneva, Switzerland 2-7 June 2018 Kobe, Japan November 2018 USA (date & location to be confirmed) 4